Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Anika Therapeutics (ANIK) EBIT Margin: 2009-2024

Historic EBIT Margin for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to -4.25%.

  • Anika Therapeutics' EBIT Margin fell 1135.00% to -11.62% in Q3 2025 from the same period last year, while for Sep 2025 it was -10.99%, marking a year-over-year decrease of 3449.00%. This contributed to the annual value of -4.25% for FY2024, which is 495.00% down from last year.
  • According to the latest figures from FY2024, Anika Therapeutics' EBIT Margin is -4.25%, which was down 708.84% from 0.70% recorded in FY2023.
  • Anika Therapeutics' 5-year EBIT Margin high stood at 3.22% for FY2022, and its period low was -21.71% during FY2020.
  • In the last 3 years, Anika Therapeutics' EBIT Margin had a median value of 0.70% in 2023 and averaged -0.11%.
  • Per our database at Business Quant, Anika Therapeutics' EBIT Margin crashed by 5,159bps in 2020 and then surged by 2,348bps in 2021.
  • Over the past 5 years, Anika Therapeutics' EBIT Margin (Yearly) stood at -21.71% in 2020, then surged by 2,348bps to 1.77% in 2021, then spiked by 145bps to 3.22% in 2022, then plummeted by 253bps to 0.70% in 2023, then tumbled by 495bps to -4.25% in 2024.